Lipoprotein-Associated Phospholipase A2 Mass Level Is Increased in Elderly Subjects with Type 2 Diabetes Mellitus
J. Fortunato,1 V. Bláha,1 J. Bis,2 J. Š2ásek,2 C. Andrýs,3 J. VojáIek,2 B. Jurašková,1 L. Sobotka,1 P. Polanský,4 and M. Brtko4 1 3rd Department of Internal Medicine, Metabolism and Gerontology, University Hospital Hradec Kralov ´ e, Medical Faculty, ´ Charles University, 50005 Hradec Kralov ´ e, Czech Republic ´ 2 1st Department of Internal Medicine, Cardioangiology, University Hospital Hradec Kralov ´ e, Medical Faculty, ´ Charles University, 50005 Hradec Kralov ´ e, Czech Republic ´ 3 Department of Immunology and Alergology, University Hospital Hradec Kralov ´ e, Medical Faculty, Charles University, ´ 50005 Hradec Kralov ´ e, Czech Republic ´ 4 Department of Cardiosurgery, University Hospital Hradec Kralov ´ e, Medical Faculty, Charles University, ´ 50005 Hradec Kralov ´ e, Czech Republic ´
Correspondence should be addressed to J. Fortunato; joaofortunato@gmail.com
Received 23 December 2013; Revised 22 February 2014; Accepted 10 March 2014; Published 10 April 2014
Academic Editor: Belma Turan Copyright © 2014 J. Fortunato et al.
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objective. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is extensively expressed by advanced atherosclerotic lesions and may play a role in plaque instability. We selected a group of elderly subjects that underwent transcatheter aortic valve implantation (TAVI) or balloon angioplasty (BA) and separated them into two groups, diabetic and nondiabetic, to compare the level of LpPLA2 mass between them.Methods. 44 patients aged 79.6 ± 5.6 years with symptomatic severe aortic valve stenosis underwent TAVI (???? = 35) or BA (????=9). 21 subjects had confirmed type 2 diabetes mellitus. Lp-PLA2 mass was measured using an enzymelinked immunosorbent assay kit (USCN Life Science, China) before and 3 days after the procedure. Results. Lp-PLA2 mass was significantly elevated in this population (1296 ± 358 ng/mL before TAVI; 1413 ± 268 ng/mL before BA) and further increased after TAVI (1604 ± 437 ng/mL, ???? < 0.01) or BA (1808 ± 303 ng/mL, ???? < 0.01). Lp-PLA2 mass was significantly increased on the diabetic group before these interventions. Conclusion. Lp-PLA2 may be a novel biomarker for the presence of rupture-prone atherosclerotic lesions in elderly patients. Levels of Lp-PLA2 in diabetic patients may accompany the higher amount of small dense LDL particles seen in these subjects.
